APY0201 | APY0201 : Inhibitor of PIKFYVE
RATINGS:
Cellular Use: (0 reviews)

In Model Organisms: (0 reviews)

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
PIKFYVE
  • IC50:5.4 nM
  • IC50:8.4 nM
  • IC50:99 nM
  • IC50:16 nM
Inhibitor
up to 300 nM

Selectivity

In Vitro Selectivity Assessment
Selectivity Assessment Description:
In situ native kinase profiling approach (KiNativ profile) using an ATP-competitive probe and Jurkat ...

Potency
Cellular
In Vitro

PIKFYVE

Mode of Action: Inhibitor

Structure-Activity-Relationship data available? No

DOI Reference: 10.1016/j.bmc.2014.03.036

In Vivo Validations

Mouse
Dose: 3 mg/Kg
Route of delivery: Intravenous
Systemic clearance: 1.0 L/h/Kg
Area Under the Curve:: 2.9 μg*h/mL
Fb : 92 %
Volume of Distribution at Steady-State: 1.2 L/Kg

DOI Reference: 10.1016/j.bmc.2014.03.036

Dose: 10 mg/Kg
Route of delivery: Intravenous
Systemic clearance: 0.8 L/h/kg
Area Under the Curve:: 12.2 μg*h/mL
Volume of Distribution at Steady-State: 0.9 L/Kg

DOI Reference: 10.1016/j.bmc.2014.03.036

Dose: 30 mg/Kg
Route of delivery: Oral
Cmax: 7.2 uM
Area Under the Curve:: 12.3 ug*h/mL
Bioavailability: 76%

DOI Reference: 10.1016/j.bmc.2014.03.036

Negative Control Compounds

cpd 6
Notes: IC50 >2000 for IL-12p70 Inhibition
SMILES: CC1=NC2=CC(C3=CC=C(N4CCNCC4)C=C3)=NN2C(N5CCOCC5)=C1

Orthogonal Probes def

YM201636
APILIMOD

Chemical Information

Molecular Formula C23H23N7O
SMILEs Cc1cccc(/C=N/Nc2cc(N3CCOCC3)n3nc(-c4ccncc4)cc3n2)c1
InChI InChI=1S/C23H23N7O/c1-17-3-2-4-18(13-17)16-25-27-21-15-23(29-9-11-31-12-10-29)30-22(26-21)14-20(28-30)19-5-7-24-8-6-19/h2-8,13-16H,9-12H2,1H3,(H,26,27)/b25-16+
Molecular weight 413.20 Da
AlogP 3.3823200000000018
HBond acceptors 8
HBond donors 1
Atoms 54

References

Cross References

canSARChEMBLBindingDB

Vendors

Note: This is not an exhaustive list and does not indicate endorsement by the portal.

Expert Reviews


No SERP comments found for APY0201

Probe APY0201 is in the process of SERP review.

Please continue to check back for new reviews and commentary.